<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the protective effect of cilostazol administrated intranasally on <z:hpo ids='HP_0011010'>chronic</z:hpo> injury after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>Cilostazol was administrated intranasally or intraperitoneally 1 h, 4 h and 7 h after the operation; then twice a day from the second day for 2 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>The neurological deficit scoring and the inclined board testing were performed within 35 d after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The survival rate, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neuron density were assessed 35 d after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULT: Intranasal cilostazol at 0.3 mg/kg increased the survival rate </plain></SENT>
<SENT sid="6" pm="."><plain>Intranasal cilostazol (0.3 mg/kg, 1 mg/kg) and intraperitoneal cilostazol (10 mg/kg) significantly attenuated neurological deficit, reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, and increased the survival neuron density in the border of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> region </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Cilostazol administered intranasally demonstrates protective effects on <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice </plain></SENT>
</text></document>